{
    "clinical_study": {
        "@rank": "65447", 
        "arm_group": [
            {
                "arm_group_label": "UMEC/VI 125/25 mcg", 
                "arm_group_type": "Experimental", 
                "description": "Combination in high dose"
            }, 
            {
                "arm_group_label": "UMEC/VI 62.5/25 mcg", 
                "arm_group_type": "Experimental", 
                "description": "Combination in low dose"
            }, 
            {
                "arm_group_label": "UMEC 125 mcg", 
                "arm_group_type": "Experimental", 
                "description": "LAMA mono in high dose"
            }, 
            {
                "arm_group_label": "UMEC 62.5 mcg", 
                "arm_group_type": "Experimental", 
                "description": "LAMA mono in low dose"
            }, 
            {
                "arm_group_label": "VI 25 mcg", 
                "arm_group_type": "Experimental", 
                "description": "LABA mono"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to assess the pharmacokinetics (PK), safety and tolerability of UMEC (62.5\u00b5g\n      and 125\u00b5g) and VI (25\u00b5g) as monotherapies and combinations in healthy Chinese subjects."
        }, 
        "brief_title": "Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Pulmonary Disease, Chronic Obstructive", 
        "condition_browse": {
            "mesh_term": [
                "Chronic Disease", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "Vilanterol trifenatate (VI) is a potent and selective long-acting \u03b22 agonist; Umeclidinium\n      bromide (UMEC) is a long-acting, inhaled, muscarinic receptor antagonist (LAMA). Both\n      compounds are in development once daily for the treatment of Chronic Obstructive Pulmonary\n      Disease (COPD).\n\n      This study is a randomized, open label, three-period crossover, balanced incomplete block\n      study which will assess the pharmacokinetics (PK), safety and tolerability of UMEC (62.5\u00b5g\n      and 125\u00b5g) and VI (25\u00b5g) as monotherapies and combinations in 20 healthy Chinese subjects.\n      Each subject will receive three of five possible treatments for 10 days each.\n\n      Blood samples for PK analysis will be taken at designed timepoints. Safety will be assessed\n      by measurement of ECG QTcF, heart rate, blood pressure, and safety laboratory data and\n      review of adverse events."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male or females at ratio of 1:1, aged 18 - 45 years . Healthy as determined\n             by a responsible and experienced physician, based on a medical evaluation including\n             medical history, physical examination, laboratory tests and cardiac monitoring.\n\n          -  Body weight \u2265 50kg and body mass index (weight/height2) within the range of 19 - 24\n             kg/m2, inclusive.\n\n          -  Male or female subjects at the time of signing the informed consent:\n\n          -  Female subject who is child-bearing potential should agree to use one of the\n             contraception methods (contraceptives intrauterine device, implantable progesterone\n             device or oral contraceptive) for an appropriate period of time (as determined by the\n             product label or investigator) prior to the start of dosing to sufficiently minimize\n             the risk of pregnancy at that point. The subjects must agree to use contraception\n             until completion of the follow-up visit.\n\n          -  Male subjects have to agree to use one of the contraception methods listed in Section\n             8.1.2. This criterion is to be followed from the time of the first dose of study\n             medication until completion of the follow-up visit\n\n          -  Normal systolic (90-139mmHg) and diastolic (60-89mmHg) blood pressure at pre-study\n             screening.\n\n          -  Subjects who are current non-smokers, who have not used any tobacco products in the 6\n             month period preceding the screening visit, and have a pack history of 10 pack years.\n             (pack years = (cigarettes per day smoked/20) \u00d7 number of years smoked)).\n\n          -  No significant abnormality on 12-lead ECG at screening, QTcF interval must be\n             <450msec (QTcF; machine or manual reading).\n\n          -  AST (SGOT), ALT (SGPT), and total-bilirubin 1.5xULN at screening. No significant\n             clinical abnormality on other laboratory tests.\n\n          -  Capable of giving written informed consent, which includes compliance with the\n             requirements and restrictions listed in the consent form.\n\n          -  Subjects who are able to use the inhalation device satisfactorily\n\n        Exclusion Criteria:\n\n          -  As a result of medical interview, physical examination or screening investigations,\n             the principle investigator or delegate physician deems the subject unsuitable for the\n             study.\n\n          -  History of mental, cardiac, renal, hepatic, significant gastrointestinal or\n             respiratory disease as judged by the investigator\n\n          -  A history of breathing problems (i.e. history of asthmatic symptomatology, unless\n             asthma in childhood that has now resolved and no longer requires maintenance therapy\n             which should not be an exclusion).\n\n          -  A chest X-ray or computed tomography (CT) scan that reveals evidence of clinically\n             significant abnormalities. A chest X-ray must be taken at day -1 of the first\n             treatment if a chest X-ray or CT scan is not available within 6 months prior to that\n             day.\n\n        History of sensitivity to heparin, heparin-induced thrombocytopenia, or sensitivity to any\n        of the study medications, or components thereof, known allergy or hypersensitivity to milk\n        protein or the excipients lactose monohydrate and magnesium stearate (MgSt), or a history\n        of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor,\n        contraindicates their participation.\n\n          -  The subject has taken prescription or non-prescription drugs, including CYP3A/PGP\n             inhibitor, vitamins, herbal and dietary supplements (including St John's Wort) within\n             7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives\n             (whichever is longer) prior to the first dose of study medication, unless in the\n             opinion of the Investigator and Sponsor the medication will not interfere with the\n             study procedures or compromise subject safety.\n\n          -  Positive result of urine cotinine test.\n\n          -  The subject has a history of cholecystectomy or biliary tract disease.\n\n          -  The subject has a significant clinical history or current conditions of glaucoma.\n\n          -  The subject has a significant clinical history or current conditions of prostatic\n             hypertrophy.\n\n          -  The subject has a positive pre-study drug screen. A minimum list of drugs that were\n             screened for included amphetamines, barbiturates, cocaine, opiates and\n             benzodiazepines. The detection of drugs with a legitimate medical use was not\n             necessarily an exclusion to study participation. The detection of alcohol was not an\n             exclusion at screening but had to be negative pre-dose and during the study.\n\n          -  History of regular alcohol consumption within 3 months of the study defined as:\n\n          -  Abuse of an average weekly intake of greater than 21 units or an average daily intake\n             of greater than three units (males), or defined as an average weekly intake of\n             greater than 14 units or an average daily intake of greater than two units (females).\n             One unit was equivalent to a half-pint (220 mL) of beer or one (25 mL) measure of\n             spirits or one glass (125 mL) of wine.\n\n          -  Female subjects, who are pregnant, planned pregnancy or lactation.\n\n          -  The subject has participated in a clinical trial and has received an investigational\n             product within the following time period prior to the first dosing day in the current\n             study: 30 days, 5 half-lives or twice the duration of the biological effect of the\n             investigational product (whichever is longer).\n\n          -  Blood donation or sampled as a study subject within three months preceding the first\n             dose of study drug and blood donation during the entire study in excess of 500mL.\n\n          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody\n             result within 3 months of screening.\n\n          -  The subject has tested positive for HIV antibodies.\n\n          -  Unwillingness or inability to follow the procedures outlined in the protocol.\n\n          -  Subject is mentally or legally incapacitated."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01899638", 
            "org_study_id": "115380"
        }, 
        "intervention": [
            {
                "arm_group_label": "UMEC/VI 125/25 mcg", 
                "description": "Combination in high dose", 
                "intervention_name": "UMEC/VI 125/25 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "UMEC/VI 62.5/25 mcg", 
                "description": "Combination in low dose", 
                "intervention_name": "UMEC/VI 62.5/25 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "UMEC 125 mcg", 
                "description": "LAMA mono in high dose", 
                "intervention_name": "UMEC 125 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "UMEC 62.5 mcg", 
                "description": "LAMA mono in low dose", 
                "intervention_name": "UMEC 62.5 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "VI 25 mcg", 
                "description": "LABA mono", 
                "intervention_name": "VI 25 mcg", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200030"
                }, 
                "name": "GSK Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Randomized, Open Label, 3 Crossover, Balanced Incomplete Block Study To Evaluate The Pharmacokinetics Of Umeclidinium Bromide and Vilanterol Trifenatate as Monotherapies and Concurrently in Healthy Chinese Subjects.", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "For both single dose and repeat dose", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "For both single dose and repeat dose", 
                "measure": "tmax", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "For both single dose and repeat dose", 
                "measure": "tlast", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "For both single dose and repeat dose", 
                "measure": "AUC0-t", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "For both single dose and repeat dose", 
                "measure": "t1/2", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "For both single dose and repeat dose", 
                "measure": "CL/F", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "For single dose", 
                "measure": "Vd/F", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "For single dose", 
                "measure": "AUC0-inf", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "For both single dose and repeat dose", 
                "measure": "AUC0-t'", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "For repeat dose", 
                "measure": "C \u03c4", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "For repeat dose", 
                "measure": "AUC0-\u03c4", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "For repeat dose", 
                "measure": "Ro", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "For repeat dose", 
                "measure": "RCmax", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "For repeat dose", 
                "measure": "DF", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01899638"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "5 months"
            }, 
            {
                "measure": "Heart rate", 
                "safety_issue": "Yes", 
                "time_frame": "5 months"
            }, 
            {
                "measure": "12-lead ECG", 
                "safety_issue": "Yes", 
                "time_frame": "5 months"
            }, 
            {
                "measure": "Chemistry", 
                "safety_issue": "Yes", 
                "time_frame": "5 months"
            }, 
            {
                "measure": "Hematology", 
                "safety_issue": "Yes", 
                "time_frame": "5 months"
            }, 
            {
                "measure": "Urinalysis", 
                "safety_issue": "Yes", 
                "time_frame": "5 months"
            }, 
            {
                "measure": "Adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "5 months"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}